UBS analyst Navin Jacob started Eli Lilly with a Buy rating and $131 price target. The analyst’s analysis suggests the company’s diabetes franchise growth, Verzenio adjuvant trial success and operating margin expansion are not fully appreciated in the stock or estimates
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.